25.10.2021 – 16:33
Investing in innovation and collaboration should increase access to health care and reach 50 million people in disadvantaged communities
- Boehringer Ingelheim announces innovations to its sustainability strategy at the World Health Summit 2021.
- The company is committed to investing EUR 250 million in collaborations to fight infectious diseases in humans and animals around the world, and to continue investing in innovation and research to control non-communicable diseases.
- In addition, Boehringer Ingelheim will continue to improve access to NCD treatment for 50 million people in disadvantaged communities.
On the occasion of the World Health Summit 2021, Boehringer Ingelheim published an update of its sustainability strategy today. The company will continue to expand its commitment under the name “Sustainable Development – For Generations”. MORE HEALTH is one of the three strategic pillars of this sustainability strategy.
Boehringer Ingelheim is thus continuing a path that began more than 135 years ago: The Group intends to tackle global challenges in the healthcare sector even more intensively by closing further gaps in healthcare based on previous successes. One focus is long-term cooperation in strong partnerships for a healthier and more sustainable future.
Specifically, Boehringer Ingelheim is intensifying its commitment in areas in which the company has specialist knowledge and resources that, on the one hand, improve the health and well-being of people with diseases and, on the other hand, benefit society as a whole. The following measures are associated with this:
- Improving access to non-communicable diseases (NCDs) treatment for 50 million people in disadvantaged communities
- Investments of EUR 250 million in partnerships and collaborations to combat infectious diseases in humans and animals
- Invest € 35 billion in innovation and research to fight non-communicable diseases (NCDs) by 2030
- Support for initiatives to cope with important challenges such as rabies and African sleeping sickness as well as the further development of parasitology with the aim of continuously integrating efficacy and environmental aspects
Hubertus von Baumbach, CEO of Boehringer Ingelheim, says: “For generations, our commitment has not only been to improve health, but also strive to change people’s lives. The need for a holistic approach that takes into account the relationships between people, animals and the environment has never been before so clearly. We believe that Boehringer Ingelheim is uniquely positioned in this area and can make an important contribution to a healthier and more sustainable future. “
The MORE HEALTH pillar of the sustainability strategy “Sustainable Development – For Generations” represents Boehringer Ingelheim’s goals of developing more effective therapies, finding better solutions to health challenges and thus contributing to a healthier world for future generations. The company is thus expanding its voluntary commitments and making an important contribution to positive developments in healthcare, society and environmental protection. This is in line with the United Nations’ Sustainable Development Goals (SDG) by 2030.
Carinne Brouillon, member of the Boehringer Ingelheim management team responsible for the Human Pharma business unit, says: “MORE HEALTH is our unique approach that addresses the health needs of humans and animals as well as their shared environment. It shows the diversity of our work and reinforces our efforts to change patients’ lives for the better by providing innovative health solutions Easier and faster to provide. To achieve this, we work with different partners around the world. “
Boehringer Ingelheim continues to invest in a number of MORE HEALTH projects and initiatives that reflect the diversity of patients and the expertise of the various partnerships. Significant milestones have already been reached in recent years, such as:
- The initiatives for patient care and product donations benefited over 150,000 people in 77 countries on all continents worldwide.
- The Angels Initiative, which is committed to expanding the network of stroke centers and “stroke-ready hospitals”, works with more than 5,400 hospitals. To date, 8.6 million stroke patients have been treated here and the level of care has been significantly improved.
- The Kuza Afya program in Kenya, which is devoted to the treatment of diabetes and high blood pressure, screened around 79,000 people for these diseases. Over 500 medical professionals were trained and treatment was given to over 5,000 previously unsupervised people.
- In 2019, a collaboration with PharmAccess was launched. The non-profit organization is committed to improving access to high-quality health care in Africa. Mobile technologies in Kenya are intended to help raise awareness of high blood pressure and diabetes in the population and to remove barriers to access to medical care.
- The Pathways Fund in Canada reaches over 20,000 people in indigenous communities and combats the prevalence of certain non-communicable diseases there.
- The Last Mile Initiative, which spans six countries in sub-Saharan Africa, has trained 7,000 smallholders to use vaccines and treatments for their animals. This enables them to optimize the health and productivity of their livestock.
- In 2020, a new pilot program to eradicate rabies was launched in Pakistan in cooperation with the World Organization for Animal Health (OIE). Boehringer Ingelheim donates the Rabisin® vaccine and collars to identify vaccinated dogs.
With the expansion and establishment of new initiatives as part of MORE HEALTH, Boehringer Ingelheim intends to additionally accelerate the achievement of the sustainability goals for 2030.
MORE HEALTH is one of three pillars of Boehringer Ingelheim’s sustainability strategy “Sustainable Development – For Generations”. With MORE POTENTIAL, the second pillar, the company wants to help shape healthy, integrative and sustainable communities. With initiatives from the third pillar, MORE GREEN, the protection of natural resources and the reduction of the CO2 footprint are promoted.
Boehringer Ingelheim works on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas with high unmet medical needs. Boehringer Ingelheim has been family-owned since it was founded in 1885 and has a long-term perspective. Around 52,000 employees serve more than 130 stores in the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. Learn more at www.boehringer-ingelheim.de
About “Sustainable Development – For Generations”
Boehringer Ingelheim is committed to improving the health of people and animals. This puts the company in a unique pioneering role in overcoming the closely interwoven challenges of sustainable development. The sustainability strategy “Sustainable Development – For Generations” has three pillars: MORE HEALTH, MORE GREEN and MORE POTENTIAL. Within these pillars, Boehringer Ingelheim pursues its goals of sustainable development with 20 global initiatives. These are in line with the United Nations’ Sustainable Development Goals. In order to achieve this, the company has expanded its commitment to working in partnership and calls for the various stakeholders to work together to tackle complex global challenges.
Head of Group Communications
Phone: +49 6132 77-173951
Head of Sustainable Development Communications
Phone: +49 6132 77-173947
Original content by: Boehringer Ingelheim, transmitted by news aktuell